Skip to content
2000
Volume 24, Issue 1
  • ISSN: 2211-3525
  • E-ISSN: 2211-3533

Abstract

is an opportunistic fungus and most common mould, both cosmopolitan and ubiquitous in nature, that causes life-threatening invasive aspergillosis and other grave infections, which pose a precise risk to patients with compromised immune systems. Despite improved therapeutic and diagnostic approaches, invasive aspergillosis remains a catastrophic fungal infection, such as COVID-19-associated pulmonary aspergillosis and influenza-associated pulmonary aspergillosis had a high prevalence in critically ill patients. It infects approximately ten million people each year, with a significantly high mortality rate. It is frequently convoluted COVID-19 and severe influenza disease by continuously challenging diagnostic and therapeutic strategies and concomitant with significant morbidity and mortality rates. However, Azole-resistant strains are rapidly emerging and creating a significant challenge in managing -associated infections. Promising new antifungal agents, including olorofim, fosmanogepix, ibrexafungerp, opelconazole, and rezafungin, are currently in clinical and preclinical trials. Treating conditions such as invasive aspergillosis, infections caused by resistant species, and those complicated by drug-drug interactions remains particularly difficult in clinical practice, highlighting the urgent need for alternative therapeutic strategies. In this review article, we highlight the characteristics and habitats of species, their pathogenicity, and the clinical challenges they pose, including diagnostic complexities. It also highlights existing and emerging therapeutic approaches for managing -associated infections. By integrating insights into the biology, diagnosis, and treatment of these infections, the review emphasizes the importance of innovative strategies to overcome current obstacles in clinical management.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/aia/10.2174/0122113525358342250120105938
2025-02-03
2026-03-09

  • From This Site

    /content/journals/aia/10.2174/0122113525358342250120105938
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. RokasA. Evolution of the human pathogenic lifestyle in fungi.Nat. Microbiol.20227560761910.1038/s41564‑022‑01112‑0 35508719
     [Google Scholar]
  2. EzeokoliO.T. GcilitshanaO. PohlC.H. Risk factors for fungal co-infections in critically ill COVID-19 patients, with a focus on immunosuppressants.J. Fungi20217754510.3390/jof7070545 34356924
     [Google Scholar]
  3. HoeniglM. LewisR. van de VeerdonkF.L. VerweijP.E. CornelyO.A. Liposomal amphotericin B-The future.J. Antimicrob. Chemother.202277Suppl. 2ii21ii3410.1093/jac/dkac353 36426674
     [Google Scholar]
  4. AlanioA. DellièreS. FodilS. BretagneS. MégarbaneB. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19.Lancet Respir. Med.202086e48e4910.1016/S2213‑2600(20)30237‑X 32445626
     [Google Scholar]
  5. PrattesJ. ValentinT. HoeniglM. TalakicE. ReisingerA.C. EllerP. Invasive pulmonary aspergillosis complicating COVID-19 in the ICU: A case report.Med. Mycol. Case Rep.2021312510.1016/j.mmcr.2020.05.001 32395423
     [Google Scholar]
  6. SamsonR.A. VisagieC.M. HoubrakenJ. HongS.B. HubkaV. KlaassenC.H.W. PerroneG. SeifertK.A. SuscaA. TanneyJ.B. VargaJ. KocsubéS. SzigetiG. YaguchiT. FrisvadJ.C. Phylogeny, identification and nomenclature of the genus Aspergillus.Stud. Mycol.201478114117310.1016/j.simyco.2014.07.004 25492982
     [Google Scholar]
  7. MeyerV. WuB. RamA.F. Aspergillus as a multi-purpose cell factory: Current status and perspectives.Biotechnol Lett.201133346910.1007/s10529‑010‑0473‑8
     [Google Scholar]
  8. PanackalA.A. LiH. KontoyiannisD.P. MoriM. PeregoC.A. BoeckhM. MarrK.A. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation.Clin. Infect. Dis.201050121588159710.1086/652761 20450414
     [Google Scholar]
  9. JensenR.H. HagenF. AstvadK.M.T. TyronA. MeisJ.F. ArendrupM.C. Azole-resistant Aspergillus fumigatus in Denmark: A laboratory-based study on resistance mechanisms and genotypes.Clin. Microbiol. Infect.2016226570.e1570.e910.1016/j.cmi.2016.04.001 27091095
     [Google Scholar]
  10. SteinbachW.J. MarrK.A. AnaissieE.J. AzieN. QuanS.P. Meier-KriescheH.U. ApewokinS. HornD.L. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry.J. Infect.201265545346410.1016/j.jinf.2012.08.003 22898389
     [Google Scholar]
  11. JensenH.L. The fungus flora of the soil.Soil Sci.193131212310.1097/00010694‑193102000‑00005
     [Google Scholar]
  12. KozakiewiczZ. SmithD. SmithJ.E. Aspergillus; Biotechnology Handbooks, Vol. 7 SmithJ.E. Boston, MASpringer199410.1007/978‑1‑4615‑2411‑3
     [Google Scholar]
  13. AbadA. Victoria Fernández-MolinaJ. BikandiJ. RamírezA. MargaretoJ. SendinoJ. Luis HernandoF. PontónJ. GaraizarJ. RementeriaA. What makes Aspergillus fumigatus a successful pathogen? Genes and molecules involved in invasive aspergillosis.Rev. Iberoam. Micol.201027415518210.1016/j.riam.2010.10.003 20974273
     [Google Scholar]
  14. AnastasiA. VareseG.C. Filipello MarchisioV. Isolation and identification of fungal communities in compost and vermicompost.Mycologia2005971334410.1080/15572536.2006.11832836 16389954
     [Google Scholar]
  15. Kwon-ChungK.J. SuguiJ.A. Aspergillus fumigatus-What makes the species a ubiquitous human fungal pathogen?PLoS Pathog.2013912e100374310.1371/journal.ppat.1003743 24348239
     [Google Scholar]
  16. LatgéJ.P. Aspergillus fumigatus and Aspergillosis.Clin. Microbiol. Rev.199912231035010.1128/CMR.12.2.310 10194462
     [Google Scholar]
  17. FrisvadJ.C. SamsonR.A. Springer. Chemotaxonomy and morphology of Aspergillus fumigatus and related taxa. Modern concepts in Penicillium and Aspergillus classification.Boston, MASpringer US199020120810.1007/978‑1‑4899‑3579‑3_17
     [Google Scholar]
  18. GibbonsJ.G. BeauvaisA. BeauR. McGaryK.L. LatgéJ.P. RokasA. Global transcriptome changes underlying colony growth in the opportunistic human pathogen Aspergillus fumigatus.Eukaryot. Cell2012111687810.1128/EC.05102‑11 21724936
     [Google Scholar]
  19. HoubrakenJ. SamsonR.A. Phylogeny of Penicillium and the segregation of trichocomaceae into three families.Stud. Mycol.201170115110.3114/sim.2011.70.01 22308045
     [Google Scholar]
  20. RaperK.B. FennellD.I. The Genus AspergillusSpringer Science+Business MediaNew York1965
     [Google Scholar]
  21. GamsW. ChristensenM. OnionsA.H. PittJ.I. SamsonR.A. Infrageneric Taxa of Aspergillus. Advances in Penicillium and Aspergillus Systematics. SamsonR.A. PittJ.I. Boston, MASpringer1985556210.1007/978‑1‑4899‑3659‑3_5
     [Google Scholar]
  22. HoubrakenJ. KocsubéS. VisagieC.M. YilmazN. WangX.C. MeijerM. KraakB. HubkaV. BenschK. SamsonR.A. FrisvadJ.C. Classification of Aspergillus, Penicillium, Talaromyces and related genera (Eurotiales): An overview of families, genera, subgenera, sections, series and species.Stud. Mycol.202095516910.1016/j.simyco.2020.05.002 32855739
     [Google Scholar]
  23. SalséM. GangneuxJ.P. CassaingS. DelhaesL. FekkarA. DupontD. BotterelF. CostaD. BourgeoisN. BouteilleB. HouzéS. DannaouiE. GueganH. CharpentierE. PersatF. FavennecL. LachaudL. SassoM. Multicentre study to determine the Etest epidemiological cut-off values of antifungal drugs in Candida spp. and Aspergillus fumigatus species complex.Clin. Microbiol. Infect.201925121546155210.1016/j.cmi.2019.04.027 31082487
     [Google Scholar]
  24. dos SantosR.A.C. SteenwykJ.L. Rivero-MenendezO. MeadM.E. SilvaL.P. BastosR.W. Alastruey-IzquierdoA. GoldmanG.H. RokasA. Genomic and phenotypic heterogeneity of clinical isolates of the human pathogens Aspergillus fumigatus, Aspergillus lentulus, and Aspergillus fumigatiaffinis.Front. Genet.20201145910.3389/fgene.2020.00459 32477406
     [Google Scholar]
  25. Rivero-MenendezO. Cuenca-EstrellaM. Alastruey-IzquierdoA. In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies.J. Antimicrob. Chemother.20197461586159010.1093/jac/dkz078 30891600
     [Google Scholar]
  26. WiederholdN.P. LockeJ.B. DaruwalaP. BartizalK. Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species.J. Antimicrob. Chemother.201873113063306710.1093/jac/dky280 30032217
     [Google Scholar]
  27. BalajeeS.A. GribskovJ.L. HanleyE. NickleD. MarrK.A. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus.Eukaryot. Cell20054362563210.1128/EC.4.3.625‑632.2005 15755924
     [Google Scholar]
  28. HagiwaraS. TamuraT. SatohK. KamewadaH. NakanoM. ShindenS. YamaguchiH. MakimuraK. The molecular identification and antifungal susceptibilities of Aspergillus species causing otomycosis in Tochigi, Japan.Mycopathologia20191841132110.1007/s11046‑018‑0299‑9 30291485
     [Google Scholar]
  29. LiF. WangB. WangL. CaoB. Phylogenetic analyses on the diversity of Aspergillus fumigatus sensu lato based on five orthologous loci.Mycopathologia20141783-416317610.1007/s11046‑014‑9790‑0 25106755
     [Google Scholar]
  30. MonteiroC. PinheiroD. MaiaM. FariaM.A. LameirasC. PintoE. Aspergillus species collected from environmental air samples in Portugal—molecular identification, antifungal susceptibility and sequencing of cyp51A gene on A. fumigatus sensu stricto itraconazole resistant.J. Appl. Microbiol.201912641140114810.1111/jam.14217 30735287
     [Google Scholar]
  31. BlatzerM. LatgéJ.P. Metal-homeostasis in the pathobiology of the opportunistic human fungal pathogen Aspergillus fumigatus.Curr. Opin. Microbiol.20174015215910.1016/j.mib.2017.11.015 29179120
     [Google Scholar]
  32. GrahlN. PuttikamonkulS. MacdonaldJ.M. GamcsikM.P. NgoL.Y. HohlT.M. CramerR.A. In vivo hypoxia and a fungal alcohol dehydrogenase influence the pathogenesis of invasive pulmonary aspergillosis.PLoS Pathog.201177e100214510.1371/journal.ppat.1002145 21811407
     [Google Scholar]
  33. KowalskiC.H. KerkaertJ.D. LiuK.W. BondM.C. HartmannR. NadellC.D. StajichJ.E. CramerR.A. Fungal biofilm morphology impacts hypoxia fitness and disease progression.Nat. Microbiol.20194122430244110.1038/s41564‑019‑0558‑7 31548684
     [Google Scholar]
  34. LatgéJ.P. BeauvaisA. ChamilosG. The cell wall of the human fungal pathogen Aspergillus fumigatus: Biosynthesis, organization, immune response, and virulence.Annu. Rev. Microbiol.20177119911610.1146/annurev‑micro‑030117‑020406 28701066
     [Google Scholar]
  35. van de VeerdonkF.L. GresnigtM.S. RomaniL. NeteaM.G. LatgéJ.P. Aspergillus fumigatus morphology and dynamic host interactions.Nat. Rev. Microbiol.2017151166167410.1038/nrmicro.2017.90 28919635
     [Google Scholar]
  36. LatgéJ.P. Tasting the fungal cell wall.Cell. Microbiol.201012786387210.1111/j.1462‑5822.2010.01474.x 20482553
     [Google Scholar]
  37. FillerS.G. SheppardD.C. Fungal invasion of normally non-phagocytic host cells.PLoS Pathog.2006212e12910.1371/journal.ppat.0020129 17196036
     [Google Scholar]
  38. RichardN. MartiL. VarrotA. GuillotL. GuitardJ. HennequinC. ImbertyA. CorvolH. ChignardM. BalloyV. Human bronchial epithelial cells inhibit Aspergillus fumigatus germination of extracellular conidia via FleA recognition.Sci. Rep.2018811569910.1038/s41598‑018‑33902‑0 30356167
     [Google Scholar]
  39. AmichJ. MokhtariZ. StrobelM. vialettoE. ShetaD. YuY. HartwegJ. KalledaN. JarickK.J. BredeC. Jordán-GarroteA.L. ThusekS. SchmiedgenK. ArslanB. PinneckerJ. ThorntonC.R. GunzerM. KrappmannS. EinseleH. HeinzeK.G. BeilhackA. Three-dimensional light sheet fluorescence microscopy of lungs to dissect local host immune-Aspergillus fumigatus interactions.MBio2020111e02752e1910.1128/mBio.02752‑19 32019790
     [Google Scholar]
  40. SeidelC. Moreno-VelásquezS.D. Ben-GhazziN. GagoS. ReadN.D. BowyerP. Phagolysosomal survival enables non-lytic hyphal escape and ramification through lung epithelium during] Aspergillus fumigatus infection.Front. Microbiol.202011195510.3389/fmicb.2020.01955 32973709
     [Google Scholar]
  41. PatinE.C. ThompsonA. OrrS.J. Pattern recognition receptors in fungal immunity.Semin. Cell Dev. Biol.201989243310.1016/j.semcdb.2018.03.003 29522806
     [Google Scholar]
  42. HeldtS. PrattesJ. EiglS. SpiessB. FlickH. RabensteinerJ. JohnsonG. PrüllerF. WölflerA. NiedristT. BochT. NeumeisterP. StrohmaierH. KrauseR. BuchheidtD. HoeniglM. Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples.J. Infect.201877323524110.1016/j.jinf.2018.05.001 29972764
     [Google Scholar]
  43. JenksJ.D. SalzerH.J.F. HoeniglM. Improving the rates of Aspergillus detection: An update on current diagnostic strategies.Expert Rev. Anti Infect. Ther.2019171395010.1080/14787210.2018.1558054 30556438
     [Google Scholar]
  44. BrownG.D. WillmentJ.A. WhiteheadL. C-type lectins in immunity and homeostasis.Nat. Rev. Immunol.201818637438910.1038/s41577‑018‑0004‑8 29581532
     [Google Scholar]
  45. FerwerdaB. FerwerdaG. PlantingaT.S. WillmentJ.A. van SprielA.B. VenselaarH. ElbersC.C. JohnsonM.D. CambiA. HuysamenC. JacobsL. JansenT. VerheijenK. MasthoffL. MorréS.A. VriendG. WilliamsD.L. PerfectJ.R. JoostenL.A.B. WijmengaC. van der MeerJ.W.M. AdemaG.J. KullbergB.J. BrownG.D. NeteaM.G. Human dectin-1 deficiency and mucocutaneous fungal infections.N. Engl. J. Med.2009361181760176710.1056/NEJMoa0901053 19864674
     [Google Scholar]
  46. FisherC.E. HohlT.M. FanW. StorerB.E. LevineD.M. ZhaoL.P. MartinP.J. WarrenE.H. BoeckhM. HansenJ.A. Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation.Blood2017129192693270110.1182/blood‑2016‑10‑743294 28270451
     [Google Scholar]
  47. StappersM.H.T. ClarkA.E. AimaniandaV. BidulaS. ReidD.M. AsamaphanP. HardisonS.E. DambuzaI.M. ValsecchiI. KerscherB. PlatoA. WallaceC.A. YuecelR. HebeckerB. da Glória Teixeira SousaM. CunhaC. LiuY. FeiziT. BrakhageA.A. Kwon-ChungK.J. GowN.A.R. ZandaM. PirasM. ZanatoC. JaegerM. NeteaM.G. van de VeerdonkF.L. LacerdaJ.F. CamposA. CarvalhoA. WillmentJ.A. LatgéJ.P. BrownG.D. Recognition of DHN-melanin by a C-type lectin receptor is required for immunity to Aspergillus.Nature2018555769638238610.1038/nature25974 29489751
     [Google Scholar]
  48. BassettiM. GiacobbeD.R. GrecchiC. RebuffiC. ZuccaroV. ScudellerL. AkovaM. Alastruey-IzquierdoA. Arikan-AkdagliS. AzoulayE. BlotS. CornelyO.A. Lass-FlörlC. KoehlerP. Cuenca-EstrellaM. de LangeD.W. De RosaF.G. De WaeleJ.J. DimopoulosG. Garnacho-MonteroJ. HoeniglM. KanjS.S. LamothF. MaertensJ. Martin-LoechesI. MuñozP. KullbergB.J. Agvald-OhmanC. PoulakouG. RelloJ. RighiE. SanguinettiM. TacconeF.S. TimsitJ-F. TorresA. VazquezJ.A. WautersJ. CalandraT. AspergesE. TejadaS. LebihanC. KaraiskosI. PeghinM. MortensenK.L. VenaA. CortegianiA. MercierT. Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with qualitative evidence synthesis.J. Infect.202081113114610.1016/j.jinf.2020.03.065 32330523
     [Google Scholar]
  49. DonnellyJ.P. ChenS.C. KauffmanC.A. SteinbachW.J. BaddleyJ.W. VerweijP.E. ClancyC.J. WingardJ.R. LockhartS.R. GrollA.H. SorrellT.C. BassettiM. AkanH. AlexanderB.D. AndesD. AzoulayE. BialekR. BradsherR.W.Jr BretagneS. CalandraT. CaliendoA.M. CastagnolaE. CrucianiM. Cuenca-EstrellaM. DeckerC.F. DesaiS.R. FisherB. HarrisonT. HeusselC.P. JensenH.E. KibblerC.C. KontoyiannisD.P. KullbergB.J. LagrouK. LamothF. LehrnbecherT. LoefflerJ. LortholaryO. MaertensJ. MarchettiO. MarrK.A. MasurH. MeisJ.F. MorriseyC.O. NucciM. Ostrosky-ZeichnerL. PaganoL. PattersonT.F. PerfectJ.R. RacilZ. RoilidesE. RuhnkeM. ProkopC.S. ShohamS. SlavinM.A. StevensD.A. ThompsonG.R.III VazquezJ.A. ViscoliC. WalshT.J. WarrisA. WheatL.J. WhiteP.L. ZaoutisT.E. PappasP.G. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of Cancer and the mycoses study group education and research consortium.Clin. Infect. Dis.20207161367137610.1093/cid/ciz1008 31802125
     [Google Scholar]
  50. WhiteP.L. ParrC. BarnesR.A. Predicting invasive aspergillosis in hematology patients by combining clinical and genetic risk factors with early diagnostic biomarkers.J. Clin. Microbiol.2017561e01122e17 29118175
     [Google Scholar]
  51. Lass-FlörlC. How to make a fast diagnosis in invasive aspergillosis.Med. Mycol.201957Suppl. 2S155S16010.1093/mmy/myy103 30816965
     [Google Scholar]
  52. CadenaJ. ThompsonG.R.III PattersonT.F. Aspergillosis: Epidemiology, diagnosis, and treatment.Infect. Dis. Clins.2021352415434 34016284
     [Google Scholar]
  53. Centers for Disease Control and Prevention. 2015. “Symptoms of Aspergillosis.” Centers for Disease Control and Prevention 4–6. https://www.cdc.gov/fungal/diseases/aspergillosis/symptoms.html
  54. BaddleyJ.W. Clinical risk factors for invasive aspergillosis.Med. Mycol.201149S1Suppl. 1S7S1210.3109/13693786.2010.505204 20718606
     [Google Scholar]
  55. LedouxM.P. GuffroyB. NivoixY. SimandC. HerbrechtR. Invasive pulmonary aspergillosis.Semin. Respir. Crit. Care Med.202041108009810.1055/s‑0039‑340199032000286
     [Google Scholar]
  56. ThompsonG.III PattersonT. Pulmonary aspergillosis: Recent advances.Semin. Respir. Crit. Care Med.201132667368110.1055/s‑0031‑1295715 22167395
     [Google Scholar]
  57. WaldA. LeisenringW. van BurikJ.A. BowdenR.A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation.J. Infect. Dis.199717561459146610.1086/516480 9180187
     [Google Scholar]
  58. KoushaM. TadiR. SoubaniA.O. Pulmonary aspergillosis: A clinical review.Eur. Respir. Rev.20112012115617410.1183/09059180.00001011 21881144
     [Google Scholar]
  59. FossesV.M. HollingsheadC.M. WaymackJ.R. Aspergillosis.StatPearls.StatPearls Publishing2023Accessed December 5, 2023. http://www.ncbi.nlm.nih.gov/books/NBK482241/
    [Google Scholar]
  60. SpanakisE.K. AperisG. MylonakisE. New agents for the treatment of fungal infections: Clinical efficacy and gaps in coverage.Clin. Infect. Dis.20064381060106810.1086/507891 16983621
     [Google Scholar]
  61. KramerM.R. DenningD.W. MarshallS.E. RossD.J. BerryG. LewistonN.J. StevensD.A. TheodoreJ. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis.Am. Rev. Respir. Dis.199155255610.1164/ajrccm/144.3_Pt_1.552 1654038
     [Google Scholar]
  62. RobinsonK.M. Mechanistic basis of super-infection: Influenza-associated invasive pulmonary aspergillosis.J. Fungi20228542810.3390/jof8050428 35628684
     [Google Scholar]
  63. VerweijP.E. RijndersB.J.A. BrüggemannR.J.M. AzoulayE. BassettiM. BlotS. CalandraT. ClancyC.J. CornelyO.A. ChillerT. DepuydtP. GiacobbeD.R. JanssenN.A.F. KullbergB.J. LagrouK. Lass-FlörlC. LewisR.E. LiuP.W.L. LortholaryO. MaertensJ. Martin-LoechesI. NguyenM.H. PattersonT.F. RogersT.R. SchoutenJ.A. SprietI. VanderbekeL. WautersJ. van de VeerdonkF.L. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: An expert opinion.Intensive Care Med.20204681524153510.1007/s00134‑020‑06091‑6 32572532
     [Google Scholar]
  64. WaldeckF. BoroliF. SuhN. Wendel GarciaP.D. FluryD. NotterJ. ItenA. KaiserL. SchrenzelJ. BoggianK. MaggioriniM. PuginJ. KlegerG.R. AlbrichW.C. Influenza-associated aspergillosis in critically-ill patients-A retrospective bicentric cohort study.Eur. J. Clin. Microbiol. Infect. Dis.202039101915192310.1007/s10096‑020‑03923‑7 32494955
     [Google Scholar]
  65. DenningD.W. PleuvryA. ColeD.C. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults.Med. Mycol.201351436137010.3109/13693786.2012.738312 23210682
     [Google Scholar]
  66. MercierT. DunbarA. de KortE. SchauwvliegheA. ReyndersM. GuldentopsE. BlijlevensN.M.A. VonkA.G. RijndersB. VerweijP.E. LagrouK. MaertensJ. Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study.Med. Mycol.202058444445210.1093/mmy/myz079 31290552
     [Google Scholar]
  67. LestradeP.P.A. MeisJ.F. MelchersW.J.G. VerweijP.E. Triazole resistance in Aspergillus fumigatus: Recent insights and challenges for patient management.Clin. Microbiol. Infect.201925779980610.1016/j.cmi.2018.11.027 30580035
     [Google Scholar]
  68. PattersonT.F. ThompsonG.R.III DenningD.W. FishmanJ.A. HadleyS. HerbrechtR. KontoyiannisD.P. MarrK.A. MorrisonV.A. NguyenM.H. SegalB.H. SteinbachW.J. StevensD.A. WalshT.J. WingardJ.R. YoungJ.A.H. BennettJ.E. Practice guidelines for the diagnosis and management of aspergillosis: 2016 Update by the infectious diseases society of America.Clin. Infect. Dis.2016634e1e6010.1093/cid/ciw326 27365388
     [Google Scholar]
  69. UllmannA.J. AguadoJ.M. Arikan-AkdagliS. DenningD.W. GrollA.H. LagrouK. Lass-FlörlC. LewisR.E. MunozP. VerweijP.E. WarrisA. AderF. AkovaM. ArendrupM.C. BarnesR.A. Beigelman-AubryC. BlotS. BouzaE. BrüggemannR.J.M. BuchheidtD. CadranelJ. CastagnolaE. ChakrabartiA. Cuenca-EstrellaM. DimopoulosG. FortunJ. GangneuxJ.P. GarbinoJ. HeinzW.J. HerbrechtR. HeusselC.P. KibblerC.C. KlimkoN. KullbergB.J. LangeC. LehrnbecherT. LöfflerJ. LortholaryO. MaertensJ. MarchettiO. MeisJ.F. PaganoL. RibaudP. RichardsonM. RoilidesE. RuhnkeM. SanguinettiM. SheppardD.C. SinkóJ. SkiadaA. VehreschildM.J.G.T. ViscoliC. CornelyO.A. Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline.Clin. Microbiol. Infect.201824Suppl. 1e1e3810.1016/j.cmi.2018.01.002 29544767
     [Google Scholar]
  70. VerweijP.E. Ananda-RajahM. AndesD. ArendrupM.C. BrüggemannR.J. ChowdharyA. CornelyO.A. DenningD.W. GrollA.H. IzumikawaK. KullbergB.J. LagrouK. MaertensJ. MeisJ.F. NewtonP. PageI. SeyedmousaviS. SheppardD.C. ViscoliC. WarrisA. DonnellyJ.P. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.Drug Resist. Updat.201521-22304010.1016/j.drup.2015.08.001 26282594
     [Google Scholar]
  71. UllmannA.J. LiptonJ.H. VesoleD.H. ChandrasekarP. LangstonA. TarantoloS.R. GreinixH. Morais de AzevedoW. ReddyV. BoparaiN. PediconeL. PatinoH. DurrantS. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.N. Engl. J. Med.2007356433534710.1056/NEJMoa061098 17251530
     [Google Scholar]
  72. JebrilN. World Health Organization Declared a pandemic public health menace: A systematic review of the coronavirus disease 2019 ‘COVID-19.’SSRN202010.2139/ssrn.3566298
     [Google Scholar]
  73. de AndradeS.A. de SouzaD.A. TorresA.L. de LimaC.F.G. EbramM.C. CelanoR.M.G. SchattnerM. Chudzinski-TavassiA.M. Pathophysiology of COVID-19: Critical role of hemostasis.Front. Cell. Infect. Microbiol.20221289697210.3389/fcimb.2022.896972
     [Google Scholar]
  74. BrownL.A.K. EllisJ. GortonR. DeS. StoneN. Surveillance for COVID-19-associated pulmonary aspergillosis.Lancet Microbe202014e15210.1016/S2666‑5247(20)30091‑4 33521717
     [Google Scholar]
  75. ErgünM. BrüggemannR.J.M. AlanioA. DellièreS. van ArkelA. BentvelsenR.G. RijpstraT. van der Sar-van der BruggeS. LagrouK. JanssenN.A.F. BuilJ.B. van DijkK. MelchersW.J.G. ReijersM.H.E. SchoutenJ.A. WautersJ. CordeyA. SoniS. WhiteP.L. van de VeerdonkF.L. VerweijP.E. Aspergillus test profiles and mortality in critically Ill COVID-19 patients.J. Clin. Microbiol.20215912e01229e2110.1128/JCM.01229‑21 34495710
     [Google Scholar]
  76. KoehlerP. CornelyO.A. BöttigerB.W. DusseF. EichenauerD.A. FuchsF. HallekM. JungN. KleinF. PersigehlT. RybnikerJ. KochanekM. BöllB. Shimabukuro-VornhagenA. COVID-19 associated pulmonary aspergillosis.Mycoses202063652853410.1111/myc.13096 32339350
     [Google Scholar]
  77. SchauwvliegheA.F.A.D. RijndersB.J.A. PhilipsN. VerwijsR. VanderbekeL. Van TienenC. LagrouK. VerweijP.E. Van de VeerdonkF.L. GommersD. SpronkP. BergmansD.C.J.J. HoedemaekersA. AndrinopoulouE.R. van den BergC.H.S.B. JuffermansN.P. HodiamontC.J. VonkA.G. DepuydtP. BoelensJ. WautersJ. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study.Lancet Respir. Med.201861078279210.1016/S2213‑2600(18)30274‑1 30076119
     [Google Scholar]
  78. RichardsonM. BowyerP. SabinoR. The human lung and Aspergillus: You are what you breathe in?Med. Mycol.201957Suppl. 2S145S15410.1093/mmy/myy149 30816978
     [Google Scholar]
  79. HashimZ. NeyazZ. MarakR.S.K. NathA. NityanandS. TripathyN.K. Practice guidelines for the diagnosis of COVID-19-associated pulmonary aspergillosis in an intensive care setting.J. Intensive Care Med.202237898599710.1177/08850666211047166 34678103
     [Google Scholar]
  80. DimopoulosG. AlmyroudiM.P. MyrianthefsP. RelloJ. BaoJ. COVID-19-associated pulmonary aspergillosis (CAPA).J. Intensive Med.202112718010.1016/j.jointm.2021.07.001 36785564
     [Google Scholar]
  81. ChangC. GershwinM.E. ThompsonG.R.III Fungal disease of the nose and sinuses: An updated overview.Curr. Allergy Asthma Rep.201313215216110.1007/s11882‑012‑0320‑1 23135919
     [Google Scholar]
  82. Peral-CagigalB. Redondo-GonzálezL.M. Verrier-HernándezA. Invasive maxillary sinus aspergillosis: A case report successfully treated with voriconazole and surgical debridement.J. Clin. Exp. Dent.201464e448e45110.4317/jced.51571 25593673
     [Google Scholar]
  83. PrajnaN.V. KrishnanT. MascarenhasJ. RajaramanR. PrajnaL. SrinivasanM. RaghavanA. OldenburgC.E. RayK.J. ZegansM.E. McLeodS.D. PorcoT.C. AcharyaN.R. LietmanT.M.; Mycotic Ulcer Treatment Trial Group, The mycotic ulcer treatment trial: A randomized trial comparing natamycin vs voriconazole.JAMA Ophthalmol.2013131442242910.1001/jamaophthalmol.2013.1497 23710492
     [Google Scholar]
  84. WalshT.J. AnaissieE.J. DenningD.W. HerbrechtR. KontoyiannisD.P. MarrK.A. MorrisonV.A. SegalB.H. SteinbachW.J. StevensD.A. van BurikJ.A. WingardJ.R. PattersonT.F. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America.Clin. Infect. Dis.200846332736010.1086/525258 18177225
     [Google Scholar]
  85. FaustinoI. RamosJ. MarizB. PapadopoulouE. GeorgakiM. NikitakisN. VargasP. Santos-SilvaA. LopesM. A rare case of mandibular Aspergillus osteomyelitis in an immunocompetent patient.Dent. J.2022101121310.3390/dj10110213 36354658
     [Google Scholar]
  86. GabrielliE. FothergillA.W. BresciniL. SuttonD.A. MarchionniE. OrsettiE. StaffolaniS. CastelliP. GesuitaR. BarchiesiF. Osteomyelitis caused by Aspergillus species: A review of 310 reported cases.Clin. Microbiol. Infect.201420655956510.1111/1469‑0691.12389 24303995
     [Google Scholar]
  87. KimM.G.J. OvertonK. Successful treatment of vertebral osteomyelitis due to Aspergillus flavus in an immunocompetent patient.BMJ Case Rep.20221511e25110110.1136/bcr‑2022‑251101 36414342
     [Google Scholar]
  88. MiceliM.H. Central nervous system infections due to Aspergillus and other hyaline molds.J. Fungi2019537910.3390/jof5030079 31480311
     [Google Scholar]
  89. ShariatiA. DidehdarM. RajaeihS. MoradabadiA. GhorbaniM. FalahatiV. CheginiZ. Aspergillosis of central nervous system in patients with leukemia and stem cell transplantation: A systematic review of case reports.Ann. Clin. Microbiol. Antimicrob.20212014410.1186/s12941‑021‑00452‑9 34130699
     [Google Scholar]
  90. ZhangM. SuX. SunW.K. ChenF. XuX.Y. ShiY. Efficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus species.Mycopathologia20141771-2111810.1007/s11046‑013‑9719‑z 24306184
     [Google Scholar]
  91. EarleK. ValeroC. ConnD.P. VereG. CookP.C. BromleyM.J. BowyerP. GagoS. Pathogenicity and virulence of Aspergillus fumigatus.Virulence2023141217226410.1080/21505594.2023.2172264 36752587
     [Google Scholar]
  92. HopeW.W. WalshT.J. DenningD.W. The invasive and saprophytic syndromes due to Aspergillus spp.Med. Mycol.200543s1Suppl. 120723810.1080/13693780400025179 16110814
     [Google Scholar]
  93. MaghrabiF. DenningD.W. The management of chronic pulmonary aspergillosis: The UK National aspergillosis centre approach.Curr. Fungal Infect. Rep.201711424225110.1007/s12281‑017‑0304‑7 29213345
     [Google Scholar]
  94. LowesD. Al-ShairK. NewtonP.J. MorrisJ. HarrisC. Rautemaa-RichardsonR. DenningD.W. Predictors of mortality in chronic pulmonary aspergillosis.Eur. Respir. J.2017492160106210.1183/13993003.01062‑2016 28179437
     [Google Scholar]
  95. MidiriA. MalatinoC. BiondoC. ZummoS. MancusoG. An unusual presentation of pulmonary aspergilloma and review of available literature.Eur. Rev. Med. Pharmacol. Sci.2022261451035106 35916807
     [Google Scholar]
  96. GreenbergerP.A. BushR.K. DemainJ.G. LuongA. SlavinR.G. KnutsenA.P. Allergic bronchopulmonary aspergillosis.J. Allergy Clin. Immunol. Pract.20142670370810.1016/j.jaip.2014.08.007 25439360
     [Google Scholar]
  97. PatelA.R. PatelA.R. SinghS. SinghS. KhawajaI. Treating allergic bronchopulmonary aspergillosis: A review.Cureus2019114e4538 31263646
     [Google Scholar]
  98. DuettmannW. KoidlC. TroppanK. SeeberK. BuzinaW. WölflerA. WagnerJ. KrauseR. HoeniglM. Serum and urine galactomannan testing for screening in patients with hematological malignancies.Med. Mycol.201452664765210.1093/mmy/myu019 24939321
     [Google Scholar]
  99. EiglS. HoeniglM. SpiessB. HeldtS. PrattesJ. NeumeisterP. WolflerA. RabensteinerJ. PruellerF. KrauseR. ReinwaldM. FlickH. BuchheidtD. BochT. Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis.Med. Mycol.2017555528534 27744310
     [Google Scholar]
  100. ZhouW. LiH. ZhangY. HuangM. HeQ. LiP. ZhangF. ShiY. SuX. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis.J. Clin. Microbiol.20175572153216110.1128/JCM.00345‑17 28446576
     [Google Scholar]
  101. KudohA. OkawaY. ShibataN. Significant structural change in both O- and N-linked carbohydrate moieties of the antigenic galactomannan from Aspergillus fumigatus grown under different culture conditions.Glycobiology2015251748710.1093/glycob/cwu091 25187160
     [Google Scholar]
  102. TortoranoA.M. EspostoM.C. PrigitanoA. GranciniA. OssiC. CavannaC. CascioG.L. Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay.J. Clin. Microbiol.20125031051105310.1128/JCM.05946‑11 22205818
     [Google Scholar]
  103. HuangY.T. HungC.C. HsuehP.R. Aspergillus galactomannan antigenemia in Penicilliosis marneffei.AIDS200721141990199110.1097/QAD.0b013e3282eeb413 17721116
     [Google Scholar]
  104. WheatL.J. HackettE. DurkinM. ConnollyP. PetraitieneR. WalshT.J. KnoxK. HageC. Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay.Clin. Vaccine Immunol.200714563864010.1128/CVI.00479‑06 17344352
     [Google Scholar]
  105. RawlingsS.A. HeldtS. PrattesJ. EiglS. JenksJ.D. FlickH. RabensteinerJ. PrüllerF. WölflerA. NeumeisterP. StrohmaierH. KrauseR. HoeniglM. Using interleukin 6 and 8 in blood and bronchoalveolar lavage fluid to predict survival in hematological malignancy patients with suspected pulmonary mold infection.Front. Immunol.201910179810.3389/fimmu.2019.01798 31428097
     [Google Scholar]
  106. de HeerK. GerritsenM.G. VisserC.E. LeeflangM.M.G. Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients.Cochrane Database System Rev.20195CD01239910.1002/14651858.CD012399.pub2 31107543
     [Google Scholar]
  107. PrattesJ. FlickH. PrüllerF. KoidlC. RaggamR.B. PalfnerM. EiglS. BuzinaW. Zollner-SchwetzI. ThorntonC.R. KrauseR. HoeniglM. Novel tests for diagnosis of invasive aspergillosis in patients with underlying respiratory diseases.Am. J. Respir. Crit. Care Med.2014190892292910.1164/rccm.201407‑1275OC 25203869
     [Google Scholar]
  108. JenksJ.D. SpiessB. BuchheidtD. HoeniglM. (New) methods for detection of Aspergillus fumigatus resistance in clinical samples.Curr. Fungal Infect. Rep.201913312913610.1007/s12281‑019‑00342‑w 31552129
     [Google Scholar]
  109. SpringerJ. LacknerM. NachbaurD. GirschikofskyM. RissleggerB. MutschlechnerW. FritzJ. HeinzW.J. EinseleH. UllmannA.J. LöfflerJ. Lass-FlörlC. Prospective multicentre PCR-based Aspergillus DNA screening in high-risk patients with and without primary antifungal mould prophylaxis.Clin. Microbiol. Infect.2016221808610.1016/j.cmi.2015.09.009 26400571
     [Google Scholar]
  110. WhiteP.L. WingardJ.R. BretagneS. LöfflerJ. PattersonT.F. SlavinM.A. BarnesR.A. PappasP.G. DonnellyJ.P. Aspergillus polymerase chain reaction: Systematic review of evidence for clinical use in comparison with antigen testing.Clin. Infect. Dis.20156181293130310.1093/cid/civ507 26113653
     [Google Scholar]
  111. EggerM. JenksJ.D. HoeniglM. PrattesJ. Blood Aspergillus PCR: The good, the bad, and the ugly.J. Fungi2020611810.3390/jof6010018 32012787
     [Google Scholar]
  112. ArvanitisM. ZiakasP.D. ZacharioudakisI.M. ZervouF.N. CaliendoA.M. MylonakisE. PCR in diagnosis of invasive aspergillosis: A meta-analysis of diagnostic performance.J. Clin. Microbiol.201452103731374210.1128/JCM.01365‑14 25122854
     [Google Scholar]
  113. HoeniglM. EiglS. HeldtS. DuettmannW. ThorntonC. PrattesJ. Clinical evaluation of the newly formatted lateral-flow device for invasive pulmonary aspergillosis.Mycoses2018611404310.1111/myc.12704 28922489
     [Google Scholar]
  114. JenksJ.D. MehtaS.R. HoeniglM. Broad spectrum triazoles for invasive mould infections in adults: Which drug and when?Med. Mycol.201957Suppl. 2S168S17810.1093/mmy/myy052 30816967
     [Google Scholar]
  115. JenksJ.D. PrattesJ. FrankJ. SpiessB. MehtaS.R. BochT. BuchheidtD. HoeniglM. Performance of the bronchoalveolar lavage fluid Aspergillus galactomannan lateral flow assay with cube reader for diagnosis of invasive pulmonary aspergillosis: A multicenter cohort study.Clin. Infect. Dis.2021737e1737e174410.1093/cid/ciaa1281 32866234
     [Google Scholar]
  116. HoeniglM. OraschT. FaserlK. PrattesJ. LoefflerJ. SpringerJ. GsallerF. ReischiesF. DuettmannW. RaggamR.B. LindnerH. HaasH. Triacetylfusarinine C: A urine biomarker for diagnosis of invasive aspergillosis.J. Infect.201978215015710.1016/j.jinf.2018.09.006 30267801
     [Google Scholar]
  117. JenksJ.D. MehtaS.R. TaplitzR. LawN. ReedS.L. HoeniglM. Bronchoalveolar lavage Aspergillus galactomannan lateral flow assay versus Aspergillus-specific lateral flow device test for diagnosis of invasive pulmonary Aspergillosis in patients with hematological malignancies.J. Infect.201978324925910.1016/j.jinf.2018.10.014 30391632
     [Google Scholar]
  118. JenksJ.D. HoeniglM. Point-of-care diagnostics for invasive aspergillosis: Nearing the finish line.Expert Rev. Mol. Diagn.202020101009101710.1080/14737159.2020.1820864 32902359
     [Google Scholar]
  119. AgarwalR. ChakrabartiA. ShahA. GuptaD. MeisJ.F. GuleriaR. MossR. DenningD.W. Allergic bronchopulmonary aspergillosis: Review of literature and proposal of new diagnostic and classification criteria.Clin. Exp. Allergy201343885087310.1111/cea.12141 23889240
     [Google Scholar]
  120. OhJ. KangC.I. KimS.H. HuhK. ChoS.Y. ChungD.R. LeeS.Y. JungC.W. PeckK.R. Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level.Mycoses2020631899410.1111/myc.13020 31610064
     [Google Scholar]
  121. SalzerH.J.F. PrattesJ. FlickH. ReimannM. HeyckendorfJ. KalsdorfB. ObersteinerS. GaedeK.I. HerzmannC. JohnsonG.L. LangeC. HoeniglM. Evaluation of galactomannan testing, the Aspergillus-specific lateral-flow device test and levels of cytokines in bronchoalveolar lavage fluid for diagnosis of chronic pulmonary aspergillosis.Front. Microbiol.20189222310.3389/fmicb.2018.02223 30333797
     [Google Scholar]
  122. DenningD.W. PageI.D. ChakayaJ. JabeenK. JudeC.M. CornetM. Alastruey-IzquierdoA. BongominF. BowyerP. ChakrabartiA. GagoS. GutoJ. HochheggerB. HoeniglM. IrfanM. IrurheN. IzumikawaK. KirengaB. MandukuV. MoazamS. OladeleR.O. RichardsonM.D. TudelaJ.L.R. RozaliyaniA. SalzerH.J.F. SawyerR. SimukulwaN.F. SkrahinaA. SriruttanC. SetianingrumF. WilopoB.A.P. ColeD.C. GetahunH. Case definition of chronic pulmonary aspergillosis in resource-constrained settings.Emerg. Infect. Dis.2018248e17131210.3201/eid2408.171312 30016256
     [Google Scholar]
  123. KauffmanC.A. FreifeldA.G. AndesD.R. BaddleyJ.W. HerwaldtL. WalkerR.C. AlexanderB.D. AnaissieE.J. BenedictK. ItoJ.I. KnappK.M. LyonG.M. MarrK.A. MorrisonV.A. ParkB.J. PattersonT.F. SchusterM.G. ChillerT.M. PappasP.G. Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the transplant-associated infection Surveillance Network (TRANSNET).Transpl. Infect. Dis.201416221322410.1111/tid.12186 24589027
     [Google Scholar]
  124. ParkH. YoukJ. ShinD.Y. HongJ. KimI. KimN.J. LeeJ.O. BangS.M. YoonS.S. ParkW.B. KohY. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.BMC Cancer201919135810.1186/s12885‑019‑5557‑9 30991992
     [Google Scholar]
  125. DudakovaA. SpiessB. TangwattanachuleepornM. SasseC. BuchheidtD. WeigM. GroßU. BaderO. Molecular tools for the detection and deduction of azole antifungal drug resistance phenotypes in Aspergillus species.Clin. Microbiol. Rev.20173041065109110.1128/CMR.00095‑16 28903985
     [Google Scholar]
  126. GeißelB. LoikoV. KlugherzI. ZhuZ. WagenerN. KurzaiO. van den HondelC.A.M.J.J. WagenerJ. Azole-induced cell wall carbohydrate patches kill Aspergillus fumigatus.Nat. Commun.201891309810.1038/s41467‑018‑05497‑7 30082817
     [Google Scholar]
  127. NeofytosD. HornD. AnaissieE. SteinbachW. OlyaeiA. FishmanJ. PfallerM. ChangC. WebsterK. MarrK. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: Analysis of multicenter Prospective Antifungal Therapy (PATH) alliance registry.Clin. Infect. Dis.200948326527310.1086/595846 19115967
     [Google Scholar]
  128. HusainS. CamargoJ.F. Invasive Aspergillosis in solid-organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.Clin. Transplant.2019339e1354410.1111/ctr.13544 30900296
     [Google Scholar]
  129. MaertensJ.A. GirmeniaC. BrüggemannR.J. DuarteR.F. KibblerC.C. LjungmanP. RacilZ. RibaudP. SlavinM.A. CornelyO.A. European guidelines for primary antifungal prophylaxis in adult haematology patients: Summary of the updated recommendations from the European Conference on Infections in Leukaemia J.Antimicrob. Chemother.201873123221323010.1093/jac/dky286
     [Google Scholar]
  130. MaertensJ.A. RahavG. LeeD.G. Ponce-de-LeónA. Ramírez SánchezI.C. KlimkoN. SonetA. HaiderS. Diego VélezJ. RaadI. KohL.P. KarthausM. ZhouJ. Ben-AmiR. MotylM.R. HanS. GrandhiA. WaskinH. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: A phase 3, randomised, controlled, non-inferiority trial.Lancet20213971027349950910.1016/S0140‑6736(21)00219‑1 33549194
     [Google Scholar]
  131. MaertensJ.A. RaadI.I. MarrK.A. PattersonT.F. KontoyiannisD.P. CornelyO.A. BowE.J. RahavG. NeofytosD. AounM. BaddleyJ.W. GiladiM. HeinzW.J. HerbrechtR. HopeW. KarthausM. LeeD.G. LortholaryO. MorrisonV.A. OrenI. SelleslagD. ShohamS. ThompsonG.R.III LeeM. MaherR.M. Schmitt-HoffmannA.H. ZeiherB. UllmannA.J. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial.Lancet20163871002076076910.1016/S0140‑6736(15)01159‑9 26684607
     [Google Scholar]
  132. BaddleyJ.W. AndesD.R. MarrK.A. KauffmanC.A. KontoyiannisD.P. ItoJ.I. SchusterM.G. BrizendineK.D. PattersonT.F. LyonG.M. BoeckhM. OsterR.A. ChillerT. PappasP.G. Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis.Med. Mycol.201351212813510.3109/13693786.2012.690108 22680976
     [Google Scholar]
  133. SchwartzS. ReismanA. TrokeP.F. The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: A retrospective analysis.Infection201139320121010.1007/s15010‑011‑0108‑6 21512792
     [Google Scholar]
  134. BoyerJ. FeysS. ZsifkovitsI. HoeniglM. EggerM. Treatment of invasive aspergillosis: How it’s going, where it’s heading.Mycopathologia2023188566768110.1007/s11046‑023‑00727‑z 37100963
     [Google Scholar]
  135. ZurlC. WallerM. SchwameisF. MuhrT. BauerN. Zollner-SchwetzI. ValentinT. MeinitzerA. UllrichE. WunschS. HoeniglM. GrinschglY. PrattesJ. OulhajA. KrauseR. Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: Outcome, tolerability and clinical implications of isavuconazole plasma concentrations.J. Fungi2020629010.3390/jof6020090 32580296
     [Google Scholar]
  136. TissotF. AgrawalS. PaganoL. PetrikkosG. GrollA.H. SkiadaA. Lass-FlörlC. CalandraT. ViscoliC. HerbrechtR. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.Haematologica20161023433
     [Google Scholar]
  137. FurfaroE. SignoriA. Di GraziaC. DominiettoA. RaiolaA.M. AquinoS. GhiggiC. GhisoA. UngaroR. AngelucciE. ViscoliC. MikulskaM. Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy.J. Antimicrob. Chemother.20197482341234610.1093/jac/dkz188 31119272
     [Google Scholar]
  138. Gómez-LópezA. Antifungal therapeutic drug monitoring: Focus on drugs without a clear recommendation.Clin. Microbiol. Infect.202026111481148710.1016/j.cmi.2020.05.037 32535150
     [Google Scholar]
  139. HöhlR. BertramR. KinzigM. HaarmeyerG.S. BaumgärtelM. GeiseA. MuschnerD. ProschD. RegerM. NaumannH.T. FickerJ.H. KubitzJ. SteinmannJ. SörgelF. Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis.Mycoses202265774775210.1111/myc.13469 35535740
     [Google Scholar]
  140. StelzerD. WeberA. IhleF. MatthesS. CeelenF. ZimmermannG. KneidingerN. SchrammR. WinterH. ZollerM. VogeserM. BehrJ. NeurohrC. Posaconazole liquid vs tablet formulation in lung transplant recipients.Mycoses201861318619410.1111/myc.12724 29110351
     [Google Scholar]
  141. PrattesJ. DuettmannW. HoeniglM. Posaconazole plasma concentrations on days three to five predict steady-state levels.Antimicrob. Agents Chemother.20166095595559910.1128/AAC.00389‑16 27324763
     [Google Scholar]
  142. HamillR.J. Amphotericin B formulations: A comparative review of efficacy and toxicity.Drugs201373991993410.1007/s40265‑013‑0069‑4 23729001
     [Google Scholar]
  143. SteimbachL.M. ToninF.S. VirtuosoS. BorbaH.H.L. SanchesA.C.C. WiensA. Fernandez-LlimósF. PontaroloR. Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.Mycoses201760314615410.1111/myc.12585 27878878
     [Google Scholar]
  144. CornelyO.A. MaertensJ. BresnikM. EbrahimiR. UllmannA.J. BouzaE. HeusselC.P. LortholaryO. RiegerC. BoehmeA. AounM. HorstH.A. ThiebautA. RuhnkeM. ReichertD. vianelliN. KrauseS.W. OlavarriaE. HerbrechtR. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).Clin. Infect. Dis.200744101289129710.1086/514341 17443465
     [Google Scholar]
  145. DuckwallM.J. GalesM.A. GalesB.J. Inhaled amphotericin B as Aspergillosis Prophylaxis in hematologic disease: An update.Microbiol. Insights201912117863611986993710.1177/1178636119869937 31496719
     [Google Scholar]
  146. MonforteV. UssettiP. LópezR. GavaldàJ. BravoC. de PabloA. PouL. PahissaA. MorellF. RománA. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: Pharmacokinetics and safety.J. Heart Lung Transplant.200928217017510.1016/j.healun.2008.11.004 19201343
     [Google Scholar]
  147. Aguilar-ZapataD. PetraitieneR. PetraitisV. Echinocandins: The expanding antifungal armamentarium.Clin. Infect. Dis.201561Suppl. 6S604S61110.1093/cid/civ814 26567277
     [Google Scholar]
  148. CornelyO.A. VehreschildJ.J. VehreschildM.J.G.T. WürthweinG. ArenzD. SchwartzS. HeusselC.P. SillingG. MahneM. FranklinJ. HarnischmacherU. WilkensA. FarowskiF. KarthausM. LehrnbecherT. UllmannA.J. HallekM. GrollA.H. Phase II dose escalation study of caspofungin for invasive Aspergillosis.Antimicrob. Agents Chemother.201155125798580310.1128/AAC.05134‑11 21911573
     [Google Scholar]
  149. ZiakasP.D. KourbetiI.S. MylonakisE. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: A meta-analysis.Clin. Ther.2014362292306.e110.1016/j.clinthera.2013.11.010 24439393
     [Google Scholar]
  150. Dodds-AshleyE. Management of drug and food interactions with azole antifungal agents in transplant recipients.Pharmacotherapy201030884285410.1592/phco.30.8.842 20653361
     [Google Scholar]
  151. BrüggemannR.J. VerheggenR. BoerrigterE. StanzaniM. VerweijP.E. BlijlevensN.M.A. LewisR.E. Management of drug–drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs.Lancet Haematol.202291e58e7210.1016/S2352‑3026(21)00232‑5 34890539
     [Google Scholar]
  152. GrollA.H. TownsendR. DesaiA. AzieN. JonesM. EngelhardtM. Schmitt-HoffmanA.H. BrüggemannR.J.M. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4.Transpl. Infect. Dis.2017195e1275110.1111/tid.12751 28722255
     [Google Scholar]
  153. TapaninenT. OlkkolaA.M. TornioA. NeuvonenM. ElonenE. NeuvonenP.J. NiemiM. BackmanJ.T. Itraconazole increases Ibrutinib exposure 10-fold and reduces interindividual variation: A potentially beneficial drug-drug interaction.Clin. Transl. Sci.202013234535110.1111/cts.12716 31664782
     [Google Scholar]
  154. PurkinsL. WoodN. KleinermansD. NicholsD. Voriconazole potentiates warfarin-induced prothrombin time prolongation.Br. J. Clin. Pharmacol.200356s1Suppl. 1242910.1046/j.1365‑2125.2003.01995.x 14616410
     [Google Scholar]
  155. VadlapatlaR.K. PatelM. PaturiD.K. PalD. MitraA.K. Clinically relevant drug–drug interactions between antiretrovirals and antifungals.Expert Opin. Drug Metab. Toxicol.201410456158010.1517/17425255.2014.883379 24521092
     [Google Scholar]
  156. KatragkouA. McCarthyM. MeletiadisJ. PetraitisV. MoradiP.W. StraussG.E. FouantM.M. KovandaL.L. PetraitieneR. RoilidesE. WalshT.J. In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.Antimicrob. Agents Chemother.201458116934693710.1128/AAC.03261‑14 25136021
     [Google Scholar]
  157. PetraitisV. PetraitieneR. McCarthyM.W. KovandaL.L. ZawM.H. HussainK. ShaikhN. MaungB.B.W. SekhonN.K. HopeW.W. WalshT.J. Combination therapy with Isavuconazole and Micafungin for treatment of experimental invasive pulmonary aspergillosis.Antimicrob. Agents Chemother.2017619e00305e0031710.1128/AAC.00305‑17 28696236
     [Google Scholar]
  158. MaertensJ. GlasmacherA. HerbrechtR. ThiebautA. CordonnierC. SegalB.H. KillarJ. TaylorA. KartsonisN. PattersonT.F. AounM. CaillotD. SableC. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.Cancer2006107122888289710.1002/cncr.22348 17103444
     [Google Scholar]
  159. MarrK.A. SchlammH.T. HerbrechtR. RottinghausS.T. BowE.J. CornelyO.A. HeinzW.J. JagannathaS. KohL.P. KontoyiannisD.P. LeeD.G. NucciM. PappasP.G. SlavinM.A. Queiroz-TellesF. SelleslagD. WalshT.J. WingardJ.R. MaertensJ.A. Combination antifungal therapy for invasive aspergillosis: A randomized trial.Ann. Intern. Med.20151622818910.7326/M13‑2508 25599346
     [Google Scholar]
  160. PanackalA.A. Combination antifungal therapy for invasive aspergillosis revisited.Med. Mycol. Open Access201622210.21767/2471‑8521.100012 27441304
     [Google Scholar]
  161. SchaffnerA. FrickP.G. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis.J. Infect. Dis.1985151590291010.1093/infdis/151.5.902 3989324
     [Google Scholar]
  162. SiopiM. SiafakasN. VourliS. ZervaL. MeletiadisJ. Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.Antimicrob. Agents Chemother.20155973973398310.1128/AAC.05035‑14 25896699
     [Google Scholar]
  163. OlsonJ.A. GeorgeA. ConstableD. SmithP. ProffittR.T. Adler-MooreJ.P. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections.Antimicrob. Agents Chemother.2015549388410.1128/AAC.01554‑09
     [Google Scholar]
  164. MihuC.N. KassisC. RamosE.R. JiangY. HachemR.Y. RaadI.I. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?Cancer2010116225290529610.1002/cncr.25312 20665889
     [Google Scholar]
  165. GeorgacopoulosO. NunnallyN. RansomE. LawD. BirchM. LockhartS. BerkowE. In vitro activity of novel antifungal olorofim against filamentous fungi and comparison to eight other antifungal agents.J. Fungi20217537810.3390/jof7050378 34065811
     [Google Scholar]
  166. KirchhoffL. DittmerS. BuerJ. RathP.M. SteinmannJ. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus.Int. J. Antimicrob. Agents202056310610510.1016/j.ijantimicag.2020.106105 32721601
     [Google Scholar]
  167. GebremariamT. GuY. AlkhazrajiS. YoussefE. ShawK.J. IbrahimA.S. The combination treatment of fosmanogepix and liposomal amphotericin B Is superior to monotherapy in treating experimental invasive mold infections.Antimicrob. Agents Chemother.2022667e00380e2210.1128/aac.00380‑22 35670592
     [Google Scholar]
  168. AnguloD.A. AlexanderB. Rautemaa-RichardsonR. Alastruey-IzquierdoA. HoeniglM. IbrahimA.S. GhannoumM.A. KingT.R. AzieN.E. WalshT.J. Ibrexafungerp, a novel triterpenoid antifungal in development for the treatment of mold infections.J. Fungi (Basel)2022811112110.3390/jof8111121 36354888
     [Google Scholar]
  169. Rivero-MenendezO. Soto-DebranJ.C. Cuenca-EstrellaM. Alastruey-IzquierdoA. In vitro activity of Ibrexafungerp against a collection of clinical isolates of Aspergillus, including cryptic species and Cyp51A mutants, using EUCAST and CLSI methodologies.J. Fungi20217323210.3390/jof7030232 33804780
     [Google Scholar]
  170. JallowS. GovenderN.P. Ibrexafungerp: A first-in-class oral triterpenoid glucan synthase inhibitor.J. Fungi20217316310.3390/jof7030163 33668824
     [Google Scholar]
  171. PrattesJ. KingT. AzieN. AnguloD.A. 466. All-cause mortality in patients with invasive candidiasis or candidemia from an interim analysis of a Phase 3 open-label study (FURI). In Open Forum Infectious Diseases. US: Oxford University Press, 2022Vol. 9Suppl 2pp. ofac49252410.1093/ofid/ofac492.524
     [Google Scholar]
  172. ColleyT. SehraG. DalyL. KimuraG. NakaokiT. NishimotoY. KizawaY. StrongP. RapeportG. ItoK. Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection.Sci. Rep.201991948210.1038/s41598‑019‑45890‑w 31263150
     [Google Scholar]
  173. HoeniglM. SpruteR. EggerM. ArastehfarA. CornelyO.A. KrauseR. Lass-FlörlC. PrattesJ. SpecA. ThompsonG.R.III WiederholdN. JenksJ.D. The antifungal pipeline: Fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin.Drugs202181151703172910.1007/s40265‑021‑01611‑0 34626339
     [Google Scholar]
  174. SandisonT. OngV. LeeJ. ThyeD. Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults.Antimicrob. Agents Chemother.2017612e01627e1610.1128/AAC.01627‑16 27919901
     [Google Scholar]
  175. MieselL. LinK.Y. OngV. Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy.Pharmacol. Res. Perspect.201976e0054610.1002/prp2.546 31763045
     [Google Scholar]
  176. SeidelM.G. PetersC. WackerA. NorthoffH. MoogR. BoehmeA. SillingG. GrimmingerW. EinseleH. Randomized phase III study of granulocyte transfusions in neutropenic patients.Bone Marrow Transplant.2008421067968410.1038/bmt.2008.237 18695660
     [Google Scholar]
  177. PerruccioK. TostiA. BurchielliE. TopiniF. RuggeriL. CarottiA. CapanniM. UrbaniE. MancusiA. AversaF. MartelliM.F. RomaniL. VelardiA. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation.Blood2005106134397440610.1182/blood‑2005‑05‑1775 16123217
     [Google Scholar]
  178. SeifM. KakoschkeT.K. EbelF. BelletM.M. TrinksN. RengaG. ParianoM. RomaniL. TappeB. EspieD. DonnadieuE. HünnigerK. HäderA. SauerM. DamotteD. AlifanoM. WhiteP.L. BackxM. NerreterT. MachwirthM. KurzaiO. PrommersbergerS. EinseleH. HudecekM. LöfflerJ. CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models.Sci. Transl. Med.202214664eabh120910.1126/scitranslmed.abh1209 36170447
     [Google Scholar]
  179. ChaiL.Y.A. Van De VeerdonkF. MarijnissenR.J. ChengS.C. KhooA.L. HectorsM. LagrouK. VonkA.G. MaertensJ. JoostenL.A.B. KullbergB.J. NeteaM.G. Anti-Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity.Immunology20101301465410.1111/j.1365‑2567.2009.03211.x 20002791
     [Google Scholar]
  180. DelsingC.E. GresnigtM.S. LeentjensJ. PreijersF. FragerF.A. KoxM. MonneretG. VenetF. Bleeker-RoversC.P. van de VeerdonkF.L. PickkersP. PachotA. KullbergB.J. NeteaM.G. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: A case series.BMC Infect. Dis.201414116610.1186/1471‑2334‑14‑166 24669841
     [Google Scholar]
  181. SerrisA. OuedraniA. UhelF. GazzanoM. BedaridaV. RouzaudC. BougnouxM.E. RaphalenJ.H. PoiréeS. LambotteO. Martin-BlondelG. LanternierF. Case report: Immune checkpoint blockade plus interferon-Γ Add-On antifungal therapy in the treatment of refractory covid-associated pulmonary aspergillosis and cerebral mucormycosis.Front. Immunol.20221390052210.3389/fimmu.2022.900522 35720319
     [Google Scholar]
  182. VuC.T.B. ThammahongA. YagitaH. AzumaM. HirankarnN. RitprajakP. LeelahavanichkulA. Blockade Of PD-1 attenuated postsepsis aspergillosis via the activation of IFN-γ and the dampening of IL-10.Shock202053451452410.1097/SHK.0000000000001392 31306346
     [Google Scholar]
  183. ColomboS.A.P. HashadR. DenningD.W. KumararatneD.S. Ceron-GutierrezL. Barcenas-MoralesG. MacDonaldA.S. HarrisC. DoffingerR. KosmidisC. Defective interferon-gamma production is common in chronic pulmonary aspergillosis.J. Infect. Dis.2022225101822183110.1093/infdis/jiab583 34850023
     [Google Scholar]
  184. WanL. ZhangY. LaiY. JiangM. SongY. ZhouJ. ZhangZ. DuanX. FuY. LiaoL. WangC. Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: A prospective multicenter randomized phase IV trial.J. Clin. Oncol.201533343999400610.1200/JCO.2014.60.5121 26392095
     [Google Scholar]
  185. WongS.S.W. DellièreS. Schiefermeier-MachN. LechnerL. PerkhoferS. BommeP. FontaineT. SchlosserA.G. SorensenG.L. MadanT. KishoreU. AimaniandaV. Surfactant protein D inhibits growth, alters cell surface polysaccharide exposure and immune activation potential of Aspergillus fumigatus.Cell Surf.2022810007210.1016/j.tcsw.2022.100072 35118215
     [Google Scholar]
  186. FernandesC.M. NormileT.G. FabriJ.H.T.M. BrauerV.S. de S AraújoG.R. FrasesS. NimrichterL. MalavaziI. Del PoetaM. Vaccination with live or Heat-Killed Aspergillus fumigatus ΔsglA conidia fully protects immunocompromised mice from invasive aspergillosis.MBio2022135e023282210.1128/mbio.02328‑22 36066100
     [Google Scholar]
  187. RayensE. RabacalW. KangS.E. CeliaB.N. MomanyM. NorrisK.A. Vaccine-induced protection in two murine models of invasive pulmonary aspergillosis.Front. Immunol.20211267057810.3389/fimmu.2021.670578 34084170
     [Google Scholar]
  188. WangY. WangK. Masso-SilvaJ.A. RiveraA. XueC. A Heat-killed Cryptococcus mutant strain induces host protection against multiple invasive mycoses in a murine vaccine model.MBio2019106e02145e1910.1128/mBio.02145‑19 31772051
     [Google Scholar]
  189. FeysS. GonçalvesS.M. KhanM. ChoiS. BoeckxB. ChatelainD. CunhaC. DebaveyeY. HermansG. HertoghsM. Humblet-BaronS. JacobsC. LagrouK. MarcelisL. MaizelJ. MeerssemanP. NygaR. SeldeslachtsL. StarickM.R. ThevissenK. VandenbrieleC. VanderbekeL. Vande VeldeG. Van RegenmortelN. VanstapelA. VanmassenhoveS. WilmerA. Van De VeerdonkF.L. De HertoghG. MombaertsP. LambrechtsD. CarvalhoA. Van WeyenberghJ. WautersJ. Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: An observational study.Lancet Respir. Med.202210121147115910.1016/S2213‑2600(22)00259‑4 36029799
     [Google Scholar]
  190. SardenN. SinhaS. PottsK.G. PernetE. HirokiC.H. HassanabadM.F. NguyenA.P. LouY. FariasR. WinstonB.W. BromleyA. SnarrB.D. ZucolotoA.Z. AndoneguiG. MuruveD.A. McDonaldB. SheppardD.C. MahoneyD.J. DivangahiM. RosinN. BiernaskieJ. YippB.G. A B1a–natural IgG–neutrophil axis is impaired in viral- and steroid-associated aspergillosis.Sci. Transl. Med.202214674eabq668210.1126/scitranslmed.abq6682 36475902
     [Google Scholar]
  191. TappeB. LauruschkatC.D. StrobelL. Pantaleón GarcíaJ. KurzaiO. RebhanS. KrausS. Pfeuffer-JovicE. BussemerL. PosslerL. HeldM. HünnigerK. KniemeyerO. SchäubleS. BrakhageA.A. PanagiotouG. WhiteP.L. EinseleH. LöfflerJ. WursterS. COVID-19 patients share common, corticosteroid-independent features of impaired host immunity to pathogenic molds.Front. Immunol.20221395498510.3389/fimmu.2022.954985 36052094
     [Google Scholar]
/content/journals/aia/10.2174/0122113525358342250120105938
Loading
The Clinical Spectrum of Aspergillus Associated Infection in Humans: A Diagnostic and Management Approach
Anti Infect. Agents 24, E22113525358342 (2026); https://doi.org/10.2174/0122113525358342250120105938
/content/journals/aia/10.2174/0122113525358342250120105938
/content/journals/aia/10.2174/0122113525358342250120105938
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): antifungal therapy; Aspergillosis; combination therapy; olorofim; opelconazole; pathogenicity

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test